Blueprint Property Plant And Equipment Net from 2010 to 2024

BPMC Stock  USD 101.41  1.40  1.36%   
Blueprint Medicines' Property Plant And Equipment Net is increasing over the years with slightly volatile fluctuation. Property Plant And Equipment Net is expected to dwindle to about 63.4 M. Property Plant And Equipment Net is the total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects Blueprint Medicines' investment in assets used for production. View All Fundamentals
 
Property Plant And Equipment Net  
First Reported
2014-12-31
Previous Quarter
115.7 M
Current Value
113.2 M
Quarterly Volatility
50.1 M
 
Yuan Drop
 
Covid
Check Blueprint Medicines financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Blueprint main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.2 M, Interest Expense of 54.2 M or Selling General Administrative of 292.2 M, as well as many exotic indicators such as Price To Sales Ratio of 21.28, Dividend Yield of 0.0 or PTB Ratio of 44.91. Blueprint financial statements analysis is a perfect complement when working with Blueprint Medicines Valuation or Volatility modules.
  
This module can also supplement Blueprint Medicines' financial leverage analysis and stock options assessment as well as various Blueprint Medicines Technical models . Check out the analysis of Blueprint Medicines Correlation against competitors.

Latest Blueprint Medicines' Property Plant And Equipment Net Growth Pattern

Below is the plot of the Property Plant And Equipment Net of Blueprint Medicines Corp over the last few years. It is the total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production. Blueprint Medicines' Property Plant And Equipment Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Blueprint Medicines' overall financial position and show how it may be relating to other accounts over time.
Property Plant And Equipment Net10 Years Trend
Slightly volatile
   Property Plant And Equipment Net   
       Timeline  

Blueprint Property Plant And Equipment Net Regression Statistics

Arithmetic Mean46,790,047
Geometric Mean14,225,245
Coefficient Of Variation109.40
Mean Deviation46,289,789
Median24,363,000
Standard Deviation51,187,728
Sample Variance2620.2T
Range119.5M
R-Value0.84
Mean Square Error820T
R-Squared0.71
Significance0.000082
Slope9,640,375
Total Sum of Squares36682.6T

Blueprint Property Plant And Equipment Net History

202463.4 M
2023115.7 M
2022115.2 M
2021120.9 M
2020101.7 M
2019111.1 M
201829.6 M

About Blueprint Medicines Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Blueprint Medicines income statement, its balance sheet, and the statement of cash flows. Blueprint Medicines investors use historical funamental indicators, such as Blueprint Medicines's Property Plant And Equipment Net, to determine how well the company is positioned to perform in the future. Although Blueprint Medicines investors may use each financial statement separately, they are all related. The changes in Blueprint Medicines's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Blueprint Medicines's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Blueprint Medicines Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Blueprint Medicines. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Property Plant And Equipment Net115.7 M63.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:
Check out the analysis of Blueprint Medicines Correlation against competitors.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Blueprint Stock analysis

When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Global Correlations
Find global opportunities by holding instruments from different markets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.82)
Revenue Per Share
4.632
Quarterly Revenue Growth
0.519
Return On Assets
(0.24)
Return On Equity
(0.80)
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.